Q-omics provides the consensus-scored KRT77 profile across patient tissues and cancer cell-line models. KRT77 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KRT77 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, KRT77 RNA expression shows 6,780 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, LUSC, and STAD as cancer lineages where KRT77 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT77 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT77 survival associations across molecular data types. KRT77 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT77 RNA expression–survival associations across cancer types. High KRT77 expression shows unfavorable associations in MESO, KIRC and KICH, but favorable associations in CESC, ESCA and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify MESO as the clearest survival context for KRT77 RNA expression.
This table summarizes KRT77 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 3. The strongest signals are observed in LUSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KRT77. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT77 shows lower tumor expression in BRCA and READ and higher tumor expression in LUSC, BLCA and KIRC. The LUSC box plot shows higher KRT77 RNA expression in tumor versus normal tissue (log2 FC = +1.124, t-test p < 0.001).
This table shows molecular features associated with KRT77 in patient tissues and cancer cell lines. In patient samples, KRT77 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, KRT77 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
